DexCom (DXCM) Director Glenn Boehnlein Receives 5,841 RSUs

What Happened

• Glenn S. Boehnlein, a director of DexCom, Inc. (DXCM), was granted 5,841 restricted stock units (RSUs) on 2026-09-10. The reported acquisition price is $0.00 (award), so no cash was paid. The filing lists the total value as $0.
• This is an award/grant (not an open-market purchase or sale) and represents a contingent right to receive one share of DexCom common stock per RSU upon vesting.

Key Details

• Transaction date: 2026-09-10. Report filed the same day (timely).
• Grant amount and price: 5,841 RSUs at $0.00 (award).
• Vesting: RSUs vest in three equal annual installments from the grant date (per footnote).
• Ownership after transaction: not specified in the provided summary of the filing.
• Footnotes:
  • F1: RSUs are exempt from Section 16b-3 and represent the contingent right to one share each; vesting in three equal annual installments.
  • F2: Shares are held by the Boehnlein 2017 Trust, for which the reporting person and spouse are co‑trustees.

Context

• RSU grants are a common form of executive/director compensation and do not reflect an immediate market purchase or sale; shares are only received if and when the RSUs vest.
• Because this is an award (code A) with a vesting schedule, it’s not a signal of immediate buying or selling activity by the insider.